Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.